Education
About Us
Working with TipRanks
Follow Us
Cuprina Holdings (Cayman) Limited Class A (CUPR)
NASDAQ:CUPR
CUPR Stock Chart & Stats
$0.38
--
Market closed
$0.38
--
Day’s Range― - ―
52-Week Range$0.28 - $9.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.90M
Market Cap
$2.95M
Enterprise Value$123.38M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.80
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding7,365,000
10 Day Avg. Volume197,362
30 Day Avg. Volume2,899,437
Financial Highlights & Ratios
PEG Ratio-2.01
Price to Book (P/B)-27.64
Price to Sales (P/S)2550.55
P/FCF Ratio-97.98
Enterprise Value/Market Cap41.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic JV Expands Product PipelineThe JV opens a clear, durable entry into the wound care market with planned clinical studies in 2026 and exposure to a large, growing addressable market. Successful development and approval would create a recurring product revenue stream beyond current offerings.
Partnership Leverages Complementary CapabilitiesThe deal structure assigns product development to Aiodine and commercialization to Cuprina, reducing the company’s R&D burden and fixed-cost investment. This leverages external technical know-how while using Cuprina’s go-to-market role to accelerate adoption with limited incremental headcount.
Slight Free Cash Flow ImprovementReported modest FCF improvement indicates initial progress toward better cash generation. If sustained, this trend can extend operating runway, reduce immediate financing needs, and provide more flexibility to fund clinical work or commercial launches tied to the JV.
Bears Say
Sharp Revenue DeclineA >50% revenue drop signals loss of customer traction or failed commercialization, undermining the company’s ability to scale. Continued top-line contraction pressures margins, hampers reinvestment capacity, and increases dependence on external capital to sustain operations.
Negative Shareholders' EquityNegative equity is a structural solvency concern that limits borrowing capacity and financial flexibility. It raises the likelihood of dilution, asset sales, or restructuring to restore balance-sheet health, increasing execution risk for multi-stage clinical or commercialization plans.
Negative Operating Cash FlowSustained negative operating cash flow drains reserves and forces repeated external financing. This weak cash-generation profile risks delaying clinical trials, product development, or commercialization of JV products and elevates execution and survival risk over the medium term.
Cuprina Holdings (Cayman) Limited Class A News
CUPR FAQ
What was Cuprina Holdings (Cayman) Limited Class A’s price range in the past 12 months?
Cuprina Holdings (Cayman) Limited Class A lowest stock price was $0.28 and its highest was $9.50 in the past 12 months.
What is Cuprina Holdings (Cayman) Limited Class A’s market cap?
Cuprina Holdings (Cayman) Limited Class A’s market cap is $2.95M.
When is Cuprina Holdings (Cayman) Limited Class A’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Cuprina Holdings (Cayman) Limited Class A’s earnings last quarter?
Currently, no data Available
Is Cuprina Holdings (Cayman) Limited Class A overvalued?
According to Wall Street analysts Cuprina Holdings (Cayman) Limited Class A’s price is currently Overvalued.
Does Cuprina Holdings (Cayman) Limited Class A pay dividends?
Cuprina Holdings (Cayman) Limited Class A does not currently pay dividends.
What is Cuprina Holdings (Cayman) Limited Class A’s EPS estimate?
Cuprina Holdings (Cayman) Limited Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cuprina Holdings (Cayman) Limited Class A have?
Cuprina Holdings (Cayman) Limited Class A has 7,365,000 shares outstanding.
What happened to Cuprina Holdings (Cayman) Limited Class A’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cuprina Holdings (Cayman) Limited Class A?
Currently, no hedge funds are holding shares in CUPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cuprina Holdings (Cayman) Limited Class A
Cuprina Holdings (Cayman) Limited is a Singapore-based biomedical and biotechnology company dedicated to developing and commercializing innovative products for managing chronic wounds. The company manufactures and distributes medical-grade sterile blowfly larvae bio-dressing products under the MEDIFLY brand, used as a biological debridement tool for chronic wounds. Additionally, Cuprina operates in the health and beauty sectors, offering cosmeceutical products.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Helius Medical Technologies
―
Windtree Therapeutics
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
―
Insiders
0.02% Mutual Funds
0.18% Other Institutional Investors
99.80% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---